Elevated Copeptin Levels Are Associated with Heart Failure Severity and Adverse Outcomes in Children with Cardiomyopathy

In children with cardiomyopathy, the severity of heart failure (HF) varies. However, copeptin, which is a biomarker of neurohormonal adaptation in heart failure, has not been studied in these patients. In this study, we evaluated the correlation of copeptin level with functional HF grading, B-type natriuretic peptide (BNP), and echocardiography variables in children with cardiomyopathy. Furthermore, we determined if copeptin levels are associated with adverse outcomes, including cardiac arrest, mechanical circulatory support, heart transplant, or death. In forty-two children with cardiomyopathy with a median (IQR) age of 13.1 years (2.5–17.2) and a median follow-up of 2.5 years (2.2–2.7), seven (16.7%) children had at least one adverse outcome. Copeptin levels were highest in the patients with adverse outcomes, followed by the patients without adverse outcomes, and then the healthy children. The copeptin levels in patients showed a strong correlation with their functional HF grading, BNP level, and left ventricular ejection fraction (LVEF). Patients with copeptin levels higher than the median value of 25 pg/mL had a higher likelihood of experiencing adverse outcomes, as revealed by Kaplan–Meier survival analysis (p = 0.024). Copeptin level was an excellent predictor of outcomes, with an area under the curve of 0.861 (95% CI, 0.634–1.089), a sensitivity of 86%, and a specificity of 60% for copeptin level of 25 pg/mL. This predictive value was superior in patients with dilated and restrictive cardiomyopathies (0.97 (CI 0.927–1.036), p < 0.0001, n = 21) than in those with hypertrophic and LV non-compaction cardiomyopathies (0.60 (CI 0.04–1.16), p = 0.7, n = 21).

[1]  M. Hersberger,et al.  Copeptin Release in Arterial Hypotension and Its Association with Severity of Disease in Critically Ill Children , 2022, Children.

[2]  Doaa El Amrousy,et al.  Predictive Value of Plasma Copeptin Level in Children with Acute Heart Failure , 2022, Pediatric Cardiology.

[3]  A. Deniz,et al.  Increased Circulating Copeptin Levels Are Associated with Vaso-Occlusive Crisis and Right Ventricular Dysfunction in Sickle Cell Anemia , 2021, Medical Principles and Practice.

[4]  Hossam A. Hodeib,et al.  Plasma copeptin levels in children with pulmonary arterial hypertension associated with congenital heart disease , 2021, European Journal of Pediatrics.

[5]  S. Goldsmith Arginine vasopressin antagonism in heart failure: Current status and possible new directions. , 2019, Journal of cardiology.

[6]  H. Yamazawa,et al.  Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH). , 2016, International journal of cardiology.

[7]  Z. Prohászka,et al.  Copeptin (C-terminal pro arginine-vasopressin) is an independent long-term prognostic marker in heart failure with reduced ejection fraction. , 2015, Heart, lung & circulation.

[8]  J. H. Lee,et al.  Vasopressin and copeptin levels in children with sepsis and septic shock , 2013, Intensive Care Medicine.

[9]  J. Towbin,et al.  Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study. , 2012, Journal of cardiac failure.

[10]  I. Gustafsson,et al.  Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. , 2012, Journal of cardiac failure.

[11]  R. Ross The Ross Classification for Heart Failure in Children After 25 Years: A Review and an Age-Stratified Revision , 2012, Pediatric Cardiology.

[12]  Song-Bin Yang,et al.  Copeptin is associated with mortality in patients with traumatic brain injury. , 2011, The Journal of trauma.

[13]  P. Ponikowski,et al.  Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin: Secondary Results From the Biomarkers in Acute Heart Failure (BACH) Study , 2011, Circulation. Heart failure.

[14]  N. Morgenthaler,et al.  Copeptin: a biomarker of cardiovascular and renal function. , 2010, Congestive heart failure.

[15]  N. Morgenthaler,et al.  The vasopressin and copeptin response to infection, severe sepsis, and septic shock* , 2009, Critical care medicine.

[16]  M. Konstam,et al.  Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia , 2008, Circulation.

[17]  J. Struck,et al.  Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. , 2008, Journal of the American College of Cardiology.

[18]  E. Braunwald,et al.  Biomarkers in heart failure. , 2008, The New England journal of medicine.

[19]  J. Struck,et al.  Copeptin: clinical use of a new biomarker , 2008, Trends in Endocrinology & Metabolism.

[20]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[21]  J. Struck,et al.  Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure , 2006, European journal of clinical investigation.

[22]  S. Colan,et al.  Incidence, causes, and outcomes of dilated cardiomyopathy in children. , 2006, JAMA.

[23]  J. Towbin,et al.  Arginine Vasopressin Levels Are Elevated and Correlate With Functional Status in Infants and Children With Congestive Heart Failure , 2004, Circulation.

[24]  J. Ghali,et al.  Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure , 2001 .

[25]  K. Kikuchi,et al.  Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. , 2000, European journal of pharmacology.

[26]  M. Packer The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[27]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[28]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[29]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[30]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[31]  N. Hollenberg,et al.  Relation of the Renin‐Angiotensin-Aldosterone System to Clinical State in Congestive Heart Failure , 1981, Circulation.

[32]  W. Chung,et al.  Pediatric Cardiomyopathies. , 2017, Circulation research.

[33]  Gail D Pearson,et al.  Heart failure in children: part I: history, etiology, and pathophysiology. , 2009, Circulation. Heart failure.

[34]  Michael Burch,et al.  New-Onset Heart Failure Due to Heart Muscle Disease in Childhood: A Prospective Study in the United Kingdom and Ireland , 2008, Circulation.